Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $6.0 million.

  • Madrigal Pharmaceuticals' Change in Account Payables fell 8387.7% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 10689.91%. This contributed to the annual value of $15.6 million for FY2024, which is 26954.87% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Change in Account Payables stood at $6.0 million for Q3 2025, which was down 8387.7% from -$4.1 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Change in Account Payables ranged from a high of $37.0 million in Q3 2024 and a low of -$11.7 million during Q1 2023
  • Moreover, its 5-year median value for Change in Account Payables was $1.4 million (2022), whereas its average is $2.3 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 546349.21% in 2021, then crashed by 93592.86% in 2023.
  • Madrigal Pharmaceuticals' Change in Account Payables (Quarter) stood at $11.0 million in 2021, then crashed by 51.93% to $5.3 million in 2022, then soared by 118.24% to $11.5 million in 2023, then crashed by 120.58% to -$2.4 million in 2024, then soared by 351.84% to $6.0 million in 2025.
  • Its Change in Account Payables was $6.0 million in Q3 2025, compared to -$4.1 million in Q2 2025 and -$1.5 million in Q1 2025.